These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3468882)

  • 1. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K
    Antimicrob Agents Chemother; 1986 Dec; 30(6):901-5. PubMed ID: 3468882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Ozawa Y
    Antimicrob Agents Chemother; 1984 Nov; 26(5):647-51. PubMed ID: 6097172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis.
    Gambertoglio JG; Alexander DP; Barriere SL
    Antimicrob Agents Chemother; 1984 Dec; 26(6):845-9. PubMed ID: 6098220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Suzuki H; Saruta T; Deguchi N; Fugono T
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1048-52. PubMed ID: 1929242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Cefmenoxime in normal and impaired renal function.
    Höffler D; Koeppe P
    Arzneimittelforschung; 1983; 33(2):269-72. PubMed ID: 6303362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of probenecid on the pharmacokinetics of cefmenoxime.
    Sennello LT; Quinn D; Rollins DE; Tolman KG; Sonders RC
    Antimicrob Agents Chemother; 1983 Jun; 23(6):803-7. PubMed ID: 6311084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.
    Sica DA; Polk RE; Kerkering TM; Patterson P; Baggett J
    Eur J Clin Pharmacol; 1986; 30(6):713-7. PubMed ID: 3464435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.
    Ohkawa M; Okasho A; Sugata T; Kuroda K
    Antimicrob Agents Chemother; 1982 Aug; 22(2):308-11. PubMed ID: 6100425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of cefmenoxime (SCE 1365-CMX) in healthy adults.
    Fourtillan JB; Bryskier A; Mignot A; Borsa F; Humbert G
    Am J Med; 1984 Dec; 77(6A):28-31. PubMed ID: 6097120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects.
    Granneman GR; Sennello LT; Steinberg FJ; Sonders RC
    Antimicrob Agents Chemother; 1982 Jan; 21(1):141-5. PubMed ID: 6282203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.
    Cohen D; Appel GB; Scully B; Neu HC
    Antimicrob Agents Chemother; 1983 Oct; 24(4):529-32. PubMed ID: 6316845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
    Kowalsky SF; Echols RM; Venezia AR; Andrews EA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):151-5. PubMed ID: 6314884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of SCE-1141, a stereoisomer of cefmenoxime, in rats.
    Kita Y; Itakura K; Tsuchiya K; Imada A
    J Antimicrob Chemother; 1986 Feb; 17(2):205-13. PubMed ID: 3457784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.